Cambridge, Massachusetts - Solarea Bio, a clinical-stage biotechnology company developing plant-based microbial solutions to some of the world's largest health problems, announced today that it has raised $15,000,000 in Series B funding. The round was led by BOLD Capital Partners, S2G Ventures, and Viking Global Investors.

The funding will be used to advance Solarea Bio's pipeline of microbiome-based therapies, which are designed to treat inflammatory processes including the gut-musculoskeletal axis. The company's novel approach to developing probiotic therapies is based on the identification and combination of microbial strains with prebiotic plant fibers.

Solarea Bio was founded in 2017 by a group of scientists and entrepreneurs eager to radically alter our understanding of the human microbiome and utilize its power to improve human health. The company's breakthrough came from the combined efforts of its co-founders who established a link between the discovery of an untapped source of microorganisms with probiotic potential in healthy foods and their applications in inflammatory processes.

"We are thrilled to have the support of such a strong group of investors," said Gerardo V. Toledo, founder of Solarea Bio. "This funding will allow us to accelerate the development of our pipeline and bring our innovative therapies to patients in need."